Diamond BioFund Inc. (6901) AI Stock Analysis

Diamond BioFund Inc.

(TWSE:6901)

Select Model

Rating:55Neutral

Price Target:TWD 14.50▲(3.57% Upside)

Action:initiatedcoverage

Date:11/09/26

Mixed financial performance driven by balance sheet strength offset by earnings instability and weak technical momentum are the primary factors; attractive low P/E valuation provides partial support.

Positive Factors

Very Low LeverageDebt-to-equity near 1% indicates a conservatively financed balance sheet and limits dependence on borrowing. This provides greater flexibility to absorb operating volatility, reduces refinancing exposure, and preserves capacity for future investment or restructuring over the coming quarters.

Negative Factors

Deep and Persistent LossesThe swing from large historical profits to deep losses indicates highly volatile and currently weak earnings power. Persistent losses can erode financial resources, reduce the ability to reinvest, and make future performance more dependent on a successful operational recovery.

Diamond BioFund Inc. (6901) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 11.86B
Dividend Yield: ―
Average Volume (3M): 1.77M
Price to Earnings (P/E): 4.1
Beta (1Y): 0.44
Revenue Growth: ―
EPS Growth: ―
Country: TW
Employees: 29
Sector: General
Sector Strength: 55
Industry: Asset Management

Diamond BioFund Inc. Business Overview & Revenue Model

Company Description

Diamond Biofund Inc. is a venture capital firm specializing in evergreen funds. The firm seeks investment in start-ups and early ventures. It typically invests in biotechnology and medical investments, including new drug R&D, high-end medical equipme...

Diamond BioFund Inc. Financial Statement Overview

Summary

Strong balance sheet with low leverage and ample equity provides stability, but this is offset by weak income statement showing revenue drops and net losses plus volatile cash flows indicating operational risks.

Income Statement

22Negative

Balance Sheet

88Very Positive

Cash Flow

35Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	3.13B	-596.00K	0	0	0	0
Gross Profit	3.10B	-28.58M	0	0	0	0
EBITDA	2.94B	-1.14B	-2.36B	-2.57B	892.83M	2.97B
Net Income	2.92B	-1.17B	-2.52B	-2.58B	797.78M	2.85B
Balance Sheet
Total Assets	12.44B	9.36B	10.67B	13.04B	11.19B	10.62B
Cash, Cash Equivalents and Short-Term Investments	2.53B	3.89B	5.13B	9.65B	10.74B	10.09B
Total Debt	81.72M	93.93M	117.83M	129.01M	3.67M	41.99M
Total Liabilities	126.00M	137.79M	301.55M	179.74M	144.06M	230.82M
Stockholders Equity	12.31B	9.22B	10.37B	12.86B	11.05B	10.39B
Cash Flow
Free Cash Flow	-77.12M	-166.11M	1.12B	-214.93M	471.04M	-300.42M
Operating Cash Flow	-76.88M	-165.92M	1.14B	-195.82M	473.09M	-300.42M
Investing Cash Flow	-410.42M	2.80B	-3.12B	-2.40B	2.48M	114.84M
Financing Cash Flow	-9.93M	-8.06M	1.02M	4.36B	-159.87M	-16.80M

Diamond BioFund Inc. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:6901 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:6901	55Neutral	TWD 11.74B	4.09	―	―	―	―
TW:6576	42Neutral	TWD 11.52B	519.28	―	―	6.41%	―
TW:6617	40Underperform	TWD 15.11B	-92.22	―	―	11.66%	-72.96%
TW:6535	39Underperform	TWD 12.33B	-33.67	―	―	-24.84%	9.09%

* General Sector Average

Performance Comparison

TW:6901 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:6901	Diamond BioFund Inc.	14.00	-4.30	-23.50%
TW:6467	TAHO Pharmaceuticals Ltd	230.00	56.50	32.56%
TW:6535	LUMOSA THERAPEUTICS CO LTD	80.80	-107.20	-57.02%
TW:6576	Foresee Pharmaceuticals Co., Ltd.	73.00	-4.50	-5.81%
TW:6589	EirGenix, Inc.	51.70	-22.80	-30.60%
TW:6617	Gongwin Biopharm Holdings Co., Ltd.	126.50	41.90	49.53%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

Diamond BioFund Inc. AI Stock Analysis